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ABSTRACT 
Purpose:  Pain is common among patients with late-stage cancer, and pain management is an important 
component of high quality cancer care.  Previous research has documented racial disparities in pain 
management for some types of cancers; however, little is known about the extent of disparities in pain 
management among individuals diagnosed with colorectal cancers.  In this study, we investigated racial 
differences in opioid use patterns among Medicare beneficiaries with newly diagnosed stage IV colorectal 
cancer who did not receive surgery after diagnosis. 
Participants:  We included individuals from the Surveillance, Epidemiology, and End Results (SEER)-
Medicare database who were greater than 66 years old, either black or white race, and newly diagnosed 
with stage IV colorectal cancer between July 2007 and December 2011.  Patients were required to have at 
least 6 months of continuous enrollment in Medicare Parts A, B, and D prior to diagnosis, continued 
through death or end of follow-up and were opioid-naïve for at least 3 months prior to their cancer 
diagnosis. 
Procedures:  We classified patients based on their recorded race in the SEER cancer registry as black or 
white. Outcome measured included whether the patient filled any opioid in the post-diagnosis period, the 
dose of first filled opioid, and any receipt of a long-acting opioid prescription. 
Statistical Analysis:  We used Kaplan-Meier analysis to compare time to opioid use by race. We used 
Cox proportional hazard models to control for other need-related characteristics. 
Results:  There were 796 white and 167 black patients included.  Approximately 56% of patients 
received opioids in the post-diagnosis period, with no difference by race (p=0.80).  White patients were 
more likely to be started at a higher average dose (53.8 MME vs. 45.2 MME, p<0.05) and were somewhat 
more likely to receive long-acting opioids (13.2% vs. 18.3%, p=0.11). 
Conclusions:  While black and white patients with late stage colorectal cancer in this cohort had similar 
use of opioid prescriptions post-diagnosis, there may be important gaps in the adequacy of pain 
management among black patients given the lower starting doses and somewhat lower likelihood of 
receiving long-acting products. 
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BACKGROUND 
 Cancer pain has been documented in 70-90% of patients with advanced stage cancer and has 
profound negative consequences on patients’ quality of life.1  Patients with cancer reporting pain may be 
less comfortable performing activities of daily living and may experience communication challenges with 
their family and caregivers.
2
  Furthermore, some studies indicate that inadequate pain control may be 
linked to poor outcomes in patients with cancer.
3
  The National Comprehensive Cancer Network (NCCN) 
recommends screening for pain at each contact with providers, and that treatment of pain should be 
titrated in a stepwise fashion based on previous strategies and level of pain.
2
  All patients should receive 
psychosocial support and nonpharmacologic therapy. In addition, it is recommended that non-opioid 
analgesics, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), should be 
considered for patients with all levels of pain.  If and when opioids are required, NCCN recommends 
starting with a short-acting low dose oral opioid such as morphine sulfate 5-15 mg before progressing to a 
long-acting opioid.  Titration of opioids and addition of a long-acting opioid should be used based on 
control of pain.
2
  In the context of advanced cancer, early integration of supportive care, including pain 
management, is considered an integral part of high quality palliative care.
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 Significant disparities have been documented between black and white patients in a variety of 
aspects of colorectal cancer including screening, diagnosis, treatments, and survival.
5,6
  White patients 
tend to be diagnosed with colorectal cancer at an earlier stage, which has been frequently linked to better 
treatment outcomes compared to black patients.
8,9
  These differences persist even when controlling for 
poverty, baseline health, tumor stage at diagnosis, gender, and treatment receipts.
8,9,10
 
 Racial disparities, specifically regarding management of cancer pain, have also been documented 
in the literature.
11,12
  One such study by Fisch, et al. found that minorities have twice the likelihood of 
white patients to be undertreated for pain resulting from breast, colorectal, lung, or prostate cancer.
11
  A 
study by Cleeland, et al. surveyed non-minority and minority patients with metastatic or recurrent cancer, 
finding that among patients with pain, 42% received analgesics weaker than recommended by the World 
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Health Organization (WHO).  Additionally, centers that served primarily black or Hispanic patients were 
three times more likely to inadequately treat pain.
12
 
 Although disparities in pain management have been described previously, no studies have 
examined population-level disparities in opioid prescribing among patients diagnosed with advanced 
stage (stage IV) colorectal cancer.  Identifying differences in opioid analgesic prescriptions between black 
and white colorectal patients with cancer may elucidate an important disparity in colorectal cancer 
symptom management and palliative care.  The present study aims to identify potential racial disparities 
in opioid utilization and dose between elderly black and white Medicare enrollees with advanced stage 
colorectal cancer.  We hypothesize that black patients will be less likely to receive opioid prescriptions, 
and among those receiving any opioid, black patients will receive them later in the course of disease, 
receive a lower first dose, and be less likely to use long-acting opioids than white patients. 
MATERIALS AND METHODS 
Data Source 
 The National Cancer Institute’s Surveillance, Epidemiology, and End Results (SEER)-Medicare 
database was used for the current study.  This data source links data from cancer registries participating in 
the SEER program with fee-for-service Medicare claims and provides detailed population-level 
information on patient cancer-related characteristics and health services use by Medicare beneficiaries 
aged 65 and older.  Specifically, the SEER registry contains information on patient demographics, tumor 
characteristics, and vital status, and the Medicare claims contain information on inpatient, outpatient, and 
pharmacy services received by enrollees. 
Inclusion and Exclusion Criteria 
 Patients were included in the study cohort if they were of black or white race as recorded in the 
SEER cancer registry and if they had a first diagnosis of stage IV colorectal cancer between July 2007 
and December 2011.  Patients were required to have six months of continuous enrollment in Medicare 
Parts A, B, and D (inpatient, outpatient, and pharmacy, respectively) prior to their cancer diagnosis and 
were followed until they died, disenrolled from fee-for-service Medicare or at December 31, 2012 (the 
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end of follow-up).  We restricted to patients aged 66 years and older at diagnosis, excluding younger 
patients who qualified for Medicare through disability.  Because we are interested in understanding 
uptake of opioid for suspected cancer-related pain, we required patients to be opioid-naïve for at least 
three months prior to diagnosis (i.e. excluding those with ongoing pain management) and we excluded 
patients who received cancer-directed surgery following diagnosis. 
Variables 
 Demographic characteristics included race (black or white), sex, age at diagnosis, marital status 
(married or unmarried), urban or rural residence and SEER region, tumor site, and year of diagnosis.  We 
also included census tract level measures of median income, poverty (percent below poverty level), and 
education (percent without a high school degree).  Cancer treatment characteristics included receipt of 
chemotherapy or radiation therapy.  Medical comorbidity was defined using the Charlson Comorbidity 
Index with the Klabunde modification.
13,14
 
Outcomes 
 The primary outcome was receipt of any opioid after diagnosis.  Secondary outcomes included 
the dose of the first opioid filled in the post-diagnosis period and whether the patient filled a long-acting 
opioid prescription.  To compare opioid dose, we standardize filled prescriptions in terms of milligram 
morphine equivalents (MME).  This measure is used to express opioid dose in terms of an equipotent 
dose of oral morphine, allowing doses to be easily compared across products. 
Statistical Analysis 
 We compared characteristics of patients using t-test for continuous variables and chi-square test 
for categorical variables.  To examine whether the cancer pain-related opioid use varied by race, we first 
used Kaplan-Meier analysis to compare the survival curves (i.e., time to cancer pain-related opioid use) 
between groups.  Follow-up started at the time of colorectal cancer diagnosis and ended with the first 
opioid fill, death, or the end of the study period.  Next, we used a Cox proportional hazards model to 
control for measured covariates (described previously) when estimating the relationship between race and 
the likelihood of opioid use.  Hazard ratios (HR) and corresponding p-values were computed for these 
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covariates. All statistical tests were performed at a significance level of α = 0.05.  The data analysis for 
this study was generated using SAS, version 9.3 (SAS Institute Inc., Cary, NC, USA). 
RESULTS 
 A total of 963 patients were included (796 white patients and 167 black patients).  Among our 
cohort, white patients were more likely to be married (41.5% vs 20.4%), and to live in census tract areas 
with higher median income and graduation rates and lower poverty.  Black patients were more likely to 
live in a big metropolitan area and live in the South than white patients.  Black patients also tended to 
have higher levels of non-cancer medical comorbidity (39.5% of black patients reporting at least one non-
cancer comorbidity versus 31.3% of white patients) and were less likely to receive chemotherapy during 
the post-diagnosis period (34.1% vs. 44.3%) (Table 1). 
Opioid Utilization 
 In the cohort, 55.1% of black patients and 56.2% of white patients received an opioid at any time 
post-diagnosis (p=0.80).  However, black patients were somewhat less likely to receive long-acting 
opioids as compared with white patients (13.2% vs. 18.3%, p=0.11) (Table 2).  Among those receiving 
any opioid, black patients appeared to be somewhat less likely to receive opioids within the first 60 days 
after diagnosis, although this was not statistically significant (Table 3). 
 When considering opioid dose, white patients were more likely to receive a higher first dose of 
opioid than black patients.  Specifically, white patients received a mean starting dose of opioid of 53.8 
MME (SD 52.1), while black patients received a mean starting dose of 45.2 MME (SD 33.8) (p<0.05).  
Expressing first opioid dose as a categorical variable of ≤ 50 MME or > 50 MME, there was no 
significant difference between groups (p=0.11) (Table 4). 
DISCUSSION 
 In this study we found that black and white patients were equally likely to receive opioids 
following a cancer diagnosis, but white patients were more likely to receive a higher first opioid dose on 
average in terms of MME.  In addition, while not statistically significant, white patients were more likely 
to start opioids earlier and to receive a long-acting opioid product during the post-diagnosis period.  
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Taken together, this may indicate that white patients are more likely than black patients with late stage 
colorectal cancer to receive adequate pain management, which supports previous literature on pain control 
between racial groups with cancer.
11,12
 
 Chronic cancer-related pain occurs in 70-90% of advanced stage patients with cancer and is a 
frequently undertreated symptom of advanced disease. Potential causes of inadequate management of 
cancer-related pain may include a lack of clinician understanding of risks of addiction or side effects, 
clinicians focusing on disease management instead of symptom management, or patients underreporting 
pain or not adhering to pain treatment regimens.
1
   The NCCN notes that patients experiencing pain may 
have difficulties performing activities of daily living and communicating with their caregivers, which may 
have detrimental effects on quality of life.
2
  There is evidence to support that early palliative care that 
includes pain management for patients with metastatic cancer improves patient quality of life, as 
compared with standard oncologic care alone.  Additionally, early palliative care in metastatic disease 
may improve survival as compared with standard oncologic care alone.
3
  Efforts should be made to ensure 
that all patients have access to appropriate pain management, particularly in the context of late stage 
disease and palliative care. 
 A number of limitations to this study were present.  First, while it is possible that observed 
differences in opioid dose are a result of racial disparities in prescribing practices, we are not able to 
determine the cause of these differences.  Second, we assume that opioids received following 
diagnosis were primarily for treating cancer-related pain, but the indication for use cannot be 
determined directly from the data source.  To attempt to address this limitation, we excluded 
patients who received an opioid in the three months before diagnosis and those who received 
surgery post-diagnosis.  However, it is possible that some opioids were prescribed for other 
conditions.  Third, some patients may be contraindicated to receiving opioids, which may falsely 
lower their respective group’s likelihood of receiving an opioid.  However, it may be unlikely 
that contraindications to opioids would differ significantly by race.  Lastly, non-prescription 
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analgesics and medications received in hospitals are not captured in this data.  If a patient is 
adequately controlled with non-prescription analgesics, it would not support a conclusion of 
racial disparities in pain control in cancer.  Additionally, patients who receive opioids during 
inpatient hospital stays may be receiving adequate opioid treatment but would not be identified 
as such in the current study.  Finally, although there were nearly 1,000 patients included in the 
current study, there were a small number of black patients (n=167) which may result in 
imprecision of some estimates. 
 Future research on racial differences in pain management among late stage cancer 
patients is warranted.  Next steps for the current project include estimating outcomes while 
controlling for sociodemographic differences, which may lessen differences seen.  Furthermore, 
patients who received surgery following diagnosis were excluded to increase homogeneity 
between patients.  However, differences in opioid use following surgery may yield similar results 
and should be explored.  Additionally, the present study only examined first use of opioids, but 
opioid dose changes over time were not assessed.  Differences in dose as opioids are titrated 
should be explored.  Because nearly all of the patients in our sample died during the study period 
we plan to evaluate differences in opioid dose during the month before death, an important 
quality consideration for palliative care for patients with end-stage disease.  Finally, we 
anticipate adding two additional years of data to the cohort within the next month, which will 
supplement the sample size for the current analysis. 
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TABLES AND FIGURES 
Table 1.  Characteristics of patients with stage IV colorectal cancer at diagnosis 
Characteristic NH White (N=796) NH Black (N=167)   p-value 
Age N (%) N (%) 0.75 
65-70 107 (13.4) 22 (13.2)   
70-75 151 (19.0) 31 (18.6)   
75-80 160 (20.1) 27 (16.2)   
80-85 161 (20.2) 35 (21.0)   
85+ 217 (27.3) 52 (31.1)   
Sex N (%) N (%) 0.3 
Female 456 (57.3) 103 (61.7)   
Male 340 (42.7) 64 (38.3)   
Marital Status N (%) N (%) < 0.001  
Married 330 (41.5)  34 (20.4)   
Single 466 (58.5)  133 (79.6)   
Year of Diagnosis N (%) N (%) 0.72 
2007 75 (9.4) 15 (9.0)   
2008 193 (24.2) 42 (25.1)   
2009 181 (22.7) 32 (19.2)   
2010 176 (22.1) 35 (21.0)   
2011 171 (21.5) 43 (25.7)   
Tumor site, N (%)     0.31 
Rectal 226 (28.4) 41 (24.6)   
Colon 570 (71.6) 126 (75.4)   
Klabunde Comorbidity 
Index, N (%) 
    < 0.001 
0 547 (68.7) 101 (60.5)   
1 160 (20.1) 28 (16.8)   
2+ 89 (11.2) 38 (22.8)   
Received radiation, N (%) 118 (14.8)  23 (13.8)  0.73 
Received chemo, N (%)  353 (44.3)  57 (34.1)  0.02 
Died, N (%) 749 (94.1)  159 (95.2)  0.57 
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Table 2.  Receipt of any opioid prescription by race 
  NH White (N=796)  NH Black (N=167)  
  N (%)  N (%)  
Received opioid  447 (56.2)  92 (55.1)  
Received long-acting opioid  146 (18.3)  22 (13.2)  
 
Table 3.  Time to first opioid prescription post-diagnosis 
  NH White (N=447)  NH Black (N=92)  
Time to first opioid Rx  N (%)  N (%)  
0-30 days  168 (37.6)  31 (33.7)  
31-60 days  141 (31.5)  23 (25.0)  
61-90 days  41 (9.2)  11 (12.0)  
91-180 days  45 (10.1)  15 (16.3)  
181-270 days  19 (4.3)  5 (5.4)  
271-365 days  8 (1.8)  2 (2.2)  
366+ days  25 (5.6)  5 (5.4)  
 
Table 4.  First opioid dose 
  NH White (N=447)  NH Black 
(N=92)  
p-value  
Average dose of first opioid 
(MME)  
Mean (SD)  Mean (SD)    
  53.8 (52.1)  45.2 (33.8)  < 0.05  
Dose of first opioid Rx  N (%)  N (%)  0.11 
≤ 50 MME  308 (68.9)  71(77.2)    
> 50 MME  139 (31.1)  21 (22.8)    
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Figure 1.  Time to first opioid prescription post-diagnosis 
 
Kaplan Meier curve for time to opioid.  Cox proportional hazard regression covariates:  Non-significant 
HR for race, age (categorical), sex, marital status, diagnosis year, tumor site, Klabunde score, reception of 
radiation.  HR for receipt of chemotherapy 1.36, p<0.01 
 
 
P=0.80 
